1-2 of 2
Mark McHale, B.S., PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity

Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Chin Hin Ng, MD MRCP, Ashish Bajel, MBBS, FRACP, FRCPA, William YK Hwang, MBBS, FRCP(London), MMed(Int MD, FAMS, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Mark McHale, B.S., PhD, Chih-Yi Hsieh, MD, Hsuan-Jen Shih, MD, Nicola McIntyre, PhD, Jamie Kwek, Wei-Ling Chang, PhD, Bertil Lindmark, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2676.
https://doi.org/10.1182/blood-2018-99-110570
Published: 2018
Journal Articles

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

Jianbiao Zhou, MD,PhD, Jessie Yiying Quah, B.S., Jing Yuan Chooi, BSc, Sabrina Hui-Min Toh, B.S., Yvonne Ng, B.S., Baohong Lin, B.S., Motomi Osato, MD, PhD, Qihui Seet, B.S., PhD, A.G. Lisa Ooi, B.S., PhD, Bertil Lindmark, MD PhD, Mark McHale, B.S., PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4047.
https://doi.org/10.1182/blood-2018-99-114392
Published: 2018